University of Chicago

IRB18-1243

A Randomized, Open-label Phase 3 Study of Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)

Dear Sir and Madame

Multiple myeloma is a hematologic malignancy and very complex disease. Symptoms are not usually recognized correctly so diagnosis can be made too late. Modern, intensive therapy can extend the life of patients and the development of newer agents has improved the outlook of relapsed disease significantly.

Taking into consideration the above-mentioned and bearing in mind the good of the patient, we would like to invite you to participate in the study named: A Randomized, Open-label Phase 3 Study of Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA).

The results of this study will help to provide evidence of efficacy and safety of this drugs and develop and optymalize the further treatment.
Biostat is responsible for eCRF
development and data management.
+48 666 069 834
support@biostat.com.pl
BioStat
Bioscience is responsible for project
management and monitoring.
+48 728 644 137
malgorzata.kubicka@bioscience.pl
Bioscience